CHEK2-associated breast cancer

Breast cancer continues to maintain its leading position in the structure of the incidence of malignant tumors among the female population. According to world statistics, the incidence of hereditary forms of breast cancer due to the presence of mutations in the genes BRCA1, BRCA2, TP53, PTEN, ATM, BRIP, PALB2, CHEK2, ranges from 5 to 10%. These genes are considered to be highly-, or moderately - and low-penetrant. The dependence of the occurrence of breast cancer on the presence of any mutation is currently relevant and actively studied direction in oncology. Many studies are devoted to patients with mutations in the BRCA1/BRCA2 genes. Currently, medical and surgical tactics of treatment and management of this category of patients have been developed. CHEK2-associated breast cancer is not less interesting, however, currently, there is no definite algorithm in the tactics of management of patients with CHEK2 mutations.